LMLucia Motlova

Lucia Motlova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lucia Motlova has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional divergence and structural changes of Class IV histone deacetylases (HDACs) across the tree of life

    by Zora Nováková, Pavla Bartošová-Sojková, Júlia Kudláčová, Fady Baselious, Zsófia Kutilová, Pavlína Jaklová, Marat Meleshin, Lucia Motlová, Andrea Schenkmayerova, Vladimír Vrkoslav, et al.

    Class IV histone deacetylases (HDACs) are the least understood branch of the classical zinc-dependent HDAC family with HDAC11 standing out as the sole member of Class IV HDACs. Using a broad phylogenetic dataset spanning bacteria, archaea, and eukaryotes, we identified two deeply conserved HDAC11 lineages, clades A and B, that differ in evolutionary origin, predicted subcellular localization, and enzymatic properties. Clade A is enriched in phototrophic eukaryotes and targeted to mitochondria or plastids, whereas clade B predominates in heterotrophs and localizes mainly to the cytoplasm or nucleus. High-resolution crystal structures of selected representatives from each clade revealed a conserved catalytic core but distinct structural features—including electrostatic surface profiles, loop architectures, and foot pocket geometries—that clearly separate the two lineages and act as sequential “selectivity filters” shaping substrate specificity. Biochemical assays show robust long-chain fatty acid deacylase activity in clade B enzymes, but no detectable activity for any of clade A representatives against peptide substrates, suggesting adaptation to alternative, nonpeptidic targets. Together, these findings define a revised evolutionary framework for HDAC11 and provide structural and functional insights into the diversification of this ancient enzyme family.


  • Open Access

    Mechanistic insights into TTLL11 polyglutamylase–mediated primary tubulin chain elongation

    by Jana Campbell, Miroslava Vosahlikova, Samar Ismail, Margareta Volnikova, Lucia Motlova, Julia Kudlacova, Kseniya Ustinova, Ivan Snajdr, Zora Novakova, Miroslav Basta, et al.

    Microtubules (MTs) undergo diverse posttranslational modifications that regulate their structural and functional properties. Among these, polyglutamylation—a dominant and conserved modification targeting unstructured tubulin C-terminal tails—plays a pivotal role in defining the tubulin code. Here, we describe a mechanism by which tubulin tyrosine ligase–like 11 (TTLL11) expands and diversifies the code. Cryo–electron microscopy revealed a unique bipartite MT recognition strategy wherein TTLL11 binding and catalytic domains engage adjacent MT protofilaments. Biochemical and cellular assays identified previously uncharacterized polyglutamylation patterns, showing that TTLL11 directly extends the primary polypeptide chains of α- and β-tubulin in vitro, challenging the prevailing paradigms emphasizing lateral branching. Moreover, cell-based and in vivo data suggest a cross-talk between polyglutamylation and the detyrosination/tyrosination cycle likely linked to the TTLL11-mediated elongation of the primary α-tubulin chain. These findings unveil an unrecognized layer of complexity within the tubulin code and offer mechanistic insights into the molecular basis of functional specialization of MT cytoskeleton.


  • Open Access

    Expanding the Tubulin Code: TTLL11 Polyglutamylase Drives Elongation of Primary Tubulin Chains

    by Jana Campbell, Miroslava Vosahlikova, Samar Ismail, Margareta Volnikova, Lucia Motlova, Julia Kudlacova, Kseniya Ustinova, Ivan Snajdr, Zora Novakova, Miroslav Basta, et al.

    Microtubules (MTs) undergo diverse post-translational modifications that regulate their structural and functional properties. Among these, polyglutamylation – a dominant and conserved modification targeting the unstructured tubulin C-terminal tails – plays a pivotal role in defining the tubulin code. Here, we uncovered a novel mechanism by which tubulin tyrosine ligase-like 11 (TTLL11) expands and diversifies the code. Cryo-electron microscopy revealed a unique bipartite MT recognition strategy wherein TTLL11’s binding and catalytic domains engage adjacent MT protofilaments. Biochemical assays identified previously unknown polyglutamylation patterns, showing that TTLL11 directly extends the primary polypeptide chains of α- and β-tubulin, challenging the prevailing paradigms emphasizing lateral branching. Moreover, cell-based and in vivo data firmly established a crosstalk between TTLL11-mediated polyglutamylation and other tubulin-modifying processes, notably the detyrosination/tyrosination cycle. This discovery unveils an unrecognized layer of complexity within the tubulin code and offers new insights into the molecular basis of functional specialization of cytoskeleton across diverse cellular contexts.


  • Open Access

    Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions

    by Martin Schäfer, Ulrike Bauder-Wüst, Mareike Roscher, Lucia Motlová, Zsófia Kutilová, Yvonne Remde, Karel D. Klika, Jürgen Graf, Cyril Bařinka, Martina Benešová-Schäfer

    PSMA-617 is recognized as a benchmark ligand for prostate-specific membrane antigen (PSMA) owing to its broad utilization in prostate cancer (PCa) targeted radionuclide therapy. In this study, the structure–activity relationships (SAR) of PSMA-617 and two novel analogs featuring modified linkers were investigated. In compounds P17 and P18, the 2-naphthyl-l-Ala moiety was replaced with a less lipophilic 3-styryl-l-Ala moiety while the cyclohexyl ring in P18 was replaced with a phenyl group. The first ever crystal structure of the PSMA/PSMA-617 complex reported here revealed a folded conformation of the PSMA-617 linker while for the PSMA/P17 and PSMA/P18 complexes, the extended orientations of the linkers revealed linker flexibility within the PSMA cavity, a change in binding that can be exploited for the structure-guided design of PSMA-targeting agents. Despite structural differences from PSMA-617, the analogs maintained high PSMA inhibition potency, cellular binding, and internalization. In vivo biodistribution studies revealed comparable tumor uptake across all three compounds with P18 displaying higher spleen accumulation, likely due to phenyl ring lipophilicity. These SAR findings provide a strategic framework for the rational design of PSMA ligands, paving the way for the development of next-generation theranostic agents for PCa.


  • R-Type Fonticins Produced by Pragia fontium Form Large Pores with High Conductance

    by Klára Látrová, Tereza Dolejšová, Lucia Motlová, Gabriela Mikušová, Juraj Bosák, Kateřina Snopková, David Šmajs, Ivo Konopásek, Radovan Fišer

    Phage tail-like bacteriocins are now the subject of research as potent antibacterial agents due to their narrow host specificity and single-hit mode of action. In this work, we focused on the structure and mode of action of fonticins.


  • Open Access

    Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer

    by Jakub Ptacek, Dong Zhang, Liming Qiu, Sven Kruspe, Lucia Motlova, Petr Kolenko, Zora Novakova, Shambhavi Shubham, Barbora Havlinova, Petra Baranova, et al.

    Prostate-specific membrane antigen (PSMA) is a well-characterized tumor marker associated with prostate cancer and neovasculature of most solid tumors. PSMA-specific ligands are thus being developed to deliver imaging or therapeutic agents to cancer cells. Here, we report on a crystal structure of human PSMA in complex with A9g, a 43-bp PSMA-specific RNA aptamer, that was determined to the 2.2 Å resolution limit. The analysis of the PSMA/aptamer interface allows for identification of key interactions critical for nanomolar binding affinity and high selectivity of A9g for human PSMA. Combined with in silico modeling, site-directed mutagenesis, inhibition experiments and cell-based assays, the structure also provides an insight into structural changes of the aptamer and PSMA upon complex formation, mechanistic explanation for inhibition of the PSMA enzymatic activity by A9g as well as its ligand-selective competition with small molecules targeting the internal pocket of the enzyme. Additionally, comparison with published protein–RNA aptamer structures pointed toward more general features governing protein-aptamer interactions. Finally, our findings can be exploited for the structure-assisted design of future A9g-based derivatives with improved binding and stability characteristics.


  • Novel β- and γ-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen

    by Kyul Kim, Hongmok Kwon, Cyril Barinka, Lucia Motlova, SangJin Nam, Doyoung Choi, Hyunsoo Ha, Hwanhee Nam, Sang-Hyun Son, Il Minn, et al.

    Prostate-specific membrane antigen (PSMA) is an excellent biomarker for the early diagnosis of prostate cancer progression and metastasis. Most promising PSMA-targeted agents in clinical phase are based on the Lys-Urea-Glu motif, in which Lys and Glu are α-(L)-amino acids. In this study, we aimed to determine the effect of β- and γ-amino acids in the S1 pocket on the binding affinity for PSMA. We synthesized and evaluated β- and γ-amino acid analogs with (S)- or (R)-configuration with keeping α-(L)-Glu as the S1'-binding pharmacophore. Structure-activity relationship studies identified that compound 13c, an β-amino acid analog with (R)-configuration, exhibited the most potent PSMA-inhibitory activity with an IC50 value of 3.97 nM. The X-ray crystal structure of PSMA in complex with 13c provided a mechanistic basis for the stereochemical preference of PSMA which can guide the development of future PSMA inhibitors.


  • Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor

    by Sida Shen, Michal Svoboda, Guangming Zhang, Maria A. Cavasin, Lucia Motlova, Timothy A. McKinsey, James H. Eubanks, Cyril Bařinka, Alan P. Kozikowski

    Tubastatin A, a tetrahydro-γ-carboline-capped selective HDAC6 inhibitor (HDAC6i), was rationally designed 10 years ago, and has become the best investigated HDAC6i to date. It shows efficacy in various neurological disease animal models, as HDAC6 plays a crucial regulatory role in axonal transport deficits, protein aggregation, as well as oxidative stress. In this work, we provide new insights into this HDAC6i by investigating the molecular basis of its interactions with HDAC6 through X-ray crystallography, determining its functional capability to elevate the levels of acetylated α-tubulin in vitro and in vivo, correlating PK/PD profiles to determine effective doses in plasma and brain, and finally assessing its therapeutic potential toward psychiatric diseases through use of the SmartCube screening platform.